Section de la LME
Tout
1. Anaesthetics, preoperative medicines and medical gases (17)
1.1. General anaesthetics and oxygen (9)
1.1.1. General anaesthetics and oxygen > Inhalational medicines (6)
1.1.2. General anaesthetics and oxygen > Injectable medicines (3)
1.2. Local anaesthetics (4)
1.3. Preoperative medication and sedation for short-term procedures (3)
1.4. Medical gases (1)
2. Medicines for pain and palliative care (30)
2.1. Non-opioids and non-steroidal anti-inflammatory medicines (NSAIMs) (4)
2.2. Opioid analgesics (8)
2.3. Medicines for other common symptoms in palliative care (18)
3. Antiallergics and medicines used in anaphylaxis (8)
4. Antidotes and other substances used in poisonings (19)
4.1. Antidotes and other substances used in poisonings > Non-specific (2)
4.2. Antidotes and other substances used in poisonings > Specific (17)
5. Medicines for diseases of the nervous system (37)
6. Anti-infective medicines (368)
6.1. Anthelminthics (44)
6.1.1. Intestinal anthelminthics (28)
6.1.2. Antifilarials (5)
6.1.3. Antischistosomals and other antitrematode medicines (7)
6.2. Antibacterials (162)
6.2.1. Access group antibiotics (62)
6.2.2. Watch group antibiotics (30)
6.2.4. Antileprosy medicines (3)
6.2.5. Antituberculosis medicines (40)
6.3. Antifungal medicines (25)
6.4. Antiviral medicines (64)
6.4.1. Antiherpes medicines (6)
6.4.2. Antiretrovirals (38)
6.4.2.1. Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors (8)
6.4.2.2. Antiretrovirals > Non-nucleoside reverse transcriptase inhibitors (2)
6.4.2.3. Antiretrovirals > Protease inhibitors (8)
6.4.2.4. Antiretrovirals > Integrase inhibitors (2)
6.4.2.6. Medicines for prevention of HIV-related opportunistic infections (1)
6.4.3. Other antivirals (3)
6.4.4. Antihepatitis medicines (17)
6.4.4.1. Medicines for hepatitis B (3)
6.4.4.1.1. Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors (3)
6.4.4.2. Medicines for hepatitis C (14)
6.4.4.2.1. Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations (6)
6.4.4.2.2. Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations (5)
6.4.4.2.3. Medicines for hepatitis C > Other antivirals for hepatitis C (3)
6.5. Antiprotozoal medicines (66)
6.5.1. Antiamoebic and antigiardiasis medicines (4)
6.5.2. Antileishmaniasis medicines (12)
6.5.4. Antipneumocystosis and antitoxoplasmosis medicines (4)
6.5.3. Antimalarial medicines (37)
6.5.3.1. Antimalarial medicines > For curative treatment (26)
6.5.3.2. Antimalarial medicines > For chemoprevention (11)
6.5.5. Antitrypanosomal medicines (9)
6.5.5.1. African trypanosomiasis (7)
6.5.5.2. American trypanosomiasis (2)
7. Antimigraine medicines (5)
7.1. Antimigraine medicines > For treatment of acute attack (4)
7.2. Antimigraine medicines > For prophylaxis (1)
8. Immunomodulators and antineoplastics (317)
8.1. Immunomodulators for non-malignant disease (22)
8.2. Antineoplastics and supportive medicines (295)
10. Medicines affecting the blood (42)
10.1. Antianaemia medicines (14)
10.2. Medicines affecting coagulation (27)
10.3. Other medicines for haemoglobinopathies (1)
11. Blood products of human origin and plasma substitutes (16)
11.1. Blood and blood components (4)
11.3. Plasma substitutes (4)
11.2. Plasma-derived medicines (8)
11.2.1. Human immunoglobulins (7)
12. Cardiovascular medicines (79)
12.1. Antianginal medicines (9)
12.2. Antiarrhythmic medicines (13)
12.3. Antihypertensive medicines (23)
12.4. Medicines used in heart failure (18)
12.6. Lipid-lowering agents (10)
12.5. Antithrombotic medicines (6)
12.5.1. Anti-platelet medicines (4)
12.5.2. Thrombolytic medicines (2)
13. Dermatological medicines (49)
13.1. Dermatological medicines > Antifungal medicines (6)
13.2. Dermatological medicines > Anti-infective medicines (7)
13.3. Dermatological medicines > Anti-inflammatory and antipruritic medicines (9)
13.4. Dermatological medicines > Medicines affecting skin differentiation and proliferation (15)
13.5. Dermatological medicines > Scabicides and pediculicides (12)
14. Diagnostic agents (8)
14.1. Diagnostic agents > Ophthalmic medicines (4)
14.2. Diagnostic agents > Radiocontrast media (4)
15. Antiseptics and disinfectants (10)
15.1. Antiseptics (6)
15.2. Disinfectants (4)
16. Diuretics (13)
17. Gastrointestinal medicines (32)
17.1. Antiulcer medicines (7)
17.2. Antiemetic medicines (9)
17.3. Anti-inflammatory medicines (9)
17.4. Laxatives (2)
17.5. Medicines used in diarrhoea (4)
17.5.1. Oral rehydration (1)
17.5.2. Medicines for diarrhoea (2)
18. Medicines for endocrine disorders (35)
18.1. Adrenal hormones and synthetic substitutes (2)
18.2. Androgens (1)
18.5. Medicines for diabetes (20)
18.4. Progestogens (3)
18.7. Thyroid hormones and antithyroid medicines (6)
19. Immunologicals (36)
19.1. Immunologicals > Diagnostic agents (1)
19.2. Immunologicals > Sera, immunoglobulins and monoclonal antibodies (8)
19.3. Immunologicals > Vaccines (27)
20. Muscle relaxants (peripherally-acting) and cholinesterase inhibitors (9)
21. Ophthalmological preparations (58)
21.1. Ophthalmological preparations > Anti-infective agents (33)
21.2. Ophthalmological preparations > Anti-inflammatory agents (4)
21.3. Ophthalmological preparations > Local anaesthetics (1)
21.4. Ophthalmological preparations > Miotics and antiglaucoma medicines (10)
21.5. Ophthalmological preparations > Mydriatics (5)
21.6. Ophthalmological preparations > Anti-vascular endothelial growth factor (VEGF) preparations (5)
22. Medicines for reproductive health and perinatal care (39)
22.3. Uterotonics (8)
22.4. Antioxytocics (tocolytics) (1)
23. Peritoneal dialysis solution (1)
24. Medicines for mental and behavioural disorders (10)
24.1. Medicines for psychotic disorders (1)
24.4. Medicines for obsessive compulsive disorders (1)
24.5. Medicines for disorders due to psychoactive substance use (4)
24.2. Medicines for mood disorders (3)
24.2.2. Medicines for bipolar disorders (3)
25. Medicines acting on the respiratory tract (26)
25.1. Antiasthmatic and medicines for chronic obstructive pulmonary disease (25)
26. Solutions correcting water, electrolyte and acid–base disturbances (11)
26.1. Solutions correcting water, electrolyte and acid-base disturbances > Oral (2)
26.2. Solutions correcting water, electrolyte and acid-base disturbances > Parenteral (8)
26.3. Solutions correcting water, electrolyte and acid-base disturbances > Miscellaneous (1)
27. Vitamins and minerals (20)
28. Ear, nose and throat medicines [c] (5)
29. Medicines for diseases of joints (20)
6.5.5.1.1. Medicines for the treatment of 1st stage African trypanosomiasis (3)
6.5.5.1.2. Medicines for the treatment of 2nd stage African trypanosomiasis (4)
6.4.2.5. Fixed-dose combinations of antiretrovirals (17)
25.2. Antitussives (1)
6.2.3. Reserve group antibiotics (27)
8.2.1. Cytotoxic medicines (195)
8.2.2. Targeted therapies (27)
8.2.3. Immunomodulators (10)
8.2.4. Hormones and antihormones (49)
8.2.5. Supportive medicines (11)
6.6. Medicines for ectoparasitic infections (1)
18.5.1. Insulins (13)
18.5.2. Oral hypoglycaemic agents (7)
18.6. Medicines for hypoglycaemia (2)
22.1. Contraceptives (18)
22.2. Ovulation inducers (1)
22.5. Other medicines administered to the mother (3)
22.6. Medicines administered to the neonate [c] (8)
22.1.1. Oral hormonal contraceptives (7)
22.1.2. Injectable hormonal contraceptives (3)
22.1.3. Intrauterine devices (2)
22.1.4. Barrier methods (2)
22.1.5. Implantable contraceptives (2)
22.1.6. Intravaginal contraceptives (2)
29.1. Medicines used to treat gout (3)
29.2. Disease-modifying anti-rheumatic drugs (DMARDs) (8)
29.3. Medicines for juvenile joint diseases (9)
19.3.1. Recommendations for all immunization programmes (15)
19.3.2. Recommendations for certain regions (3)
19.3.3. Recommendations for some high-risk populations (6)
19.3.4. Recommendations for immunization programmes with certain characteristics (3)
17.6. Pancreatic enzymes (1)
6.1.4. Cysticidal medicines (4)
30. Dental medicines and preparations (2)
6.7. Medicines for Ebola virus disease (2)
5.1. Antiseizure medicines (25)
5.2. Medicines for multiple sclerosis (6)
5.3. Medicines for parkinsonism (4)
6.8. Medicines for COVID-19 (1)
24.5.2. Medicines for nicotine use disorders (2)
24.5.3. Medicines for opioid use disorders (2)
Indication
Tout
Malignant neoplasms of prostate (11)
Malignant neoplasms of breast (6)
Lymphoid leukaemia, not elsewhere classified (5)
Burkitt lymphoma including Burkitt leukaemia (4)
Plasma cell myeloma (3)
Anaplastic large cell lymphoma, ALK-positive (3)
Anaplastic large cell lymphoma, ALK-negative (3)
Follicular lymphoma (2)
Diffuse large B-cell lymphomas (2)
Chronic lymphocytic leukaemia or small lymphocytic lymphoma (2)
Hodgkin lymphoma (2)
Langerhans cell histiocytosis (2)
Unspecified malignant neoplasms of ill-defined or unspecified sites (2)
Other specified malignant neoplasms of breast (2)
Ajouté pour la première fois
Tout
1977 (1)
1979 (0)
1982 (0)
1984 (3)
1987 (0)
1989 (0)
1991 (0)
1993 (0)
1995 (0)
1997 (0)
1999 (0)
2002 (0)
2003 (1)
2005 (0)
2007 (0)
2009 (0)
2011 (4)
2013 (0)
2015 (20)
2017 (0)
2019 (7)
2021 (3)
2023 (8)
Population cible
Âge
Tout
Adolescents et adultes (48)
Enfants (1 mois - 12 ans) (1)
Nouveau-né (< 1 mois) (0)
Sexe
Tout
Féminin (0)
Mâle (8)
Tous (41)
Liste modèle des médicaments essentiels